Approved Oncology Deal Benchmarks

Median Upfront

$2.1B

Range: $1.5B - $2.5B

Total Deal Value

$5.7B

Range: $4.8B - $6.5B

Royalty Rate

19.3% - 30%

Tiered up to 34%

Dev Milestones

$180M

Range: $164M - $203M

Model Your Deal

Market Analysis

Approved oncology licensing deals carry a median total deal value of $5.7B, with upfront payments ranging from $1.5B to $2.5B. At this stage, deal structures are shifted toward higher upfront allocations, reflecting reduced regulatory risk and near-term commercial potential. The recommended split allocates 37% to upfront and 63% to milestones.

The oncology landscape at the approved stage is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. Development milestones average $180M, regulatory milestones contribute $898M, and commercial milestones reach $2.5B. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors.

Royalty rates for approved oncology deals range from 19.3% to 30% at the base tier, with high-tier escalation to 34%. The reduced risk profile at this stage justifies higher fixed royalty commitments.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for approved oncology deals?

Approved oncology deals average $2.1B in upfront payments, ranging from $1.5B to $2.5B. The upfront allocation of 37% of total deal value reflects the clinical stage risk profile.

How are approved oncology deal milestones structured?

Milestones account for approximately 63% of total deal value. Development milestones ($180M) represent the largest component, followed by commercial milestones ($2.5B) and regulatory milestones ($898M).

What royalty rates are typical for approved oncology licensing?

Base royalty rates range from 19.3% to 30%, with tiered escalation to 23.3%-34% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Approved Oncology Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Preclinical Oncology Deals

Phase 1 Oncology Deals

Approved Neurology Deals

Approved Immunology & Autoimmune Deals

Ready to Calculate Your Deal Terms?